KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash & Equivalents (2016 - 2026)

Neogenomics filings provide 17 years of Cash & Equivalents readings, the most recent being $146.1 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 57.79% to $146.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $146.1 million, a 57.79% decrease, with the full-year FY2025 number at $159.6 million, down 56.51% from a year prior.
  • Cash & Equivalents hit $146.1 million in Q1 2026 for Neogenomics, down from $159.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $367.0 million in Q4 2024 to a low of $146.1 million in Q1 2026.
  • Median Cash & Equivalents over the past 5 years was $289.1 million (2023), compared with a mean of $277.6 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 30.13% in 2023 and later crashed 57.79% in 2026.
  • Neogenomics' Cash & Equivalents stood at $263.2 million in 2022, then surged by 30.13% to $342.5 million in 2023, then grew by 7.16% to $367.0 million in 2024, then tumbled by 56.51% to $159.6 million in 2025, then dropped by 8.44% to $146.1 million in 2026.
  • The last three reported values for Cash & Equivalents were $146.1 million (Q1 2026), $159.6 million (Q4 2025), and $164.1 million (Q3 2025) per Business Quant data.